crypto can, Overview

(1) First, there was an obvious shrinkage in the opening today. My understanding is that I bought what I should have bought yesterday and sold what I should have sold yesterday. Today, the market has risen, and everyone will not be so impulsive. Therefore, the main funds in the venue are self-directed.Because yesterday, when the mood was the highest, it was inevitable that the turnover would be enlarged. Today, everyone has calmed down, and the volume will drop. Everyone's willingness to trade is not so strong. Some major institutions have done more by themselves. Typically, they don't want everyone to make money.At this time, institutions will either choose some high dividends or some oversold industry leaders as a defense. Those who want to catch the daily limit and buy and sell in day trading are more likely to lose money.

If you choose the right direction, the rest is the problem of holding shares. If you don't find the right direction, you will increase your workload.(2) Second, the appreciation of RMB exchange rate is obvious today. Yesterday's trend made everyone dissatisfied, but yesterday's exchange rate performance was very firm. Some people say that the exchange rate strength has anything to do with investors?Strategically speaking, today's index should be a weak rebound, so the index surprise is not expected.

1. Now the market has returned to the human nature stage of opening higher and going lower, opening lower and going higher. I've been watching more emotional outbursts and higher prices, but it happened that the market was calmed down by smashing the market, and everyone was more pessimistic. When I felt that the low price was going to plummet, the main institutions stood up and pulled up.Everyone still tries to choose the direction of holding shares and wait patiently for the policy to be fulfilled.The plates were those that opened higher yesterday, and they have been further repaired today. At the end of the year, don't always think about chasing the daily limit, low-level consumer medicine, and the industry's low valuation leader, holding it steadily in the cyclical direction.